ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Etidronate (United States: Not available): Drug information

Etidronate (United States: Not available): Drug information
(For additional information see "Etidronate (United States: Not available): Patient drug information" and see "Etidronate (United States: Not available): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • ACT Etidronate [DSC];
  • CO Etidronate [DSC]
Pharmacologic Category
  • Bisphosphonate Derivative
Dosing: Adult

Note: Etidronate 200 mg and 400 mg tablets have been discontinued in the United States for >1 year.

Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.

Paget disease

Paget disease: Oral:

Initial: 5 mg/kg/day (not to exceed 6 months) is recommended as initial therapy; if higher doses are needed, may give 5 to 10 mg/kg/day (not to exceed 6 months) or 11 to 20 mg/kg/day (not to exceed 3 months). Doses >10 mg/kg/day should be used only when lower doses are ineffective or there is a need to suppress rapid bone turnover (ie, potential for irreversible neurologic damage) or reduce elevated cardiac output. Doses >20 mg/kg/day are not recommended.

Re-treatment: Initiate only after etidronate-free period ≥90 days. Monitor patients every 3 to 6 months. Re-treatment regimens are the same as for initial treatment. In cases where the original dose is not adequate, consider increasing the dose within the recommended guidelines.

Heterotopic ossification

Heterotopic ossification: Oral:

Caused by spinal cord injury: 20 mg/kg/day for 2 weeks, then 10 mg/kg/day for 10 weeks; total treatment period: 12 weeks

Complicating total hip replacement: 20 mg/kg/day for 1 month preoperatively then 20 mg/kg/day for 3 months postoperatively; total treatment period is 4 months

Re-treatment: Has not been studied.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Manufacturer’s labeling recommends decreasing the dose when GFR is reduced; however, no specific dosage adjustments are provided. Use with caution and monitor closely; etidronate is eliminated intact via the kidneys.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing. Use with caution and monitor closely.

Dosing: Pediatric

(For additional information see "Etidronate (United States: Not available): Pediatric drug information")

Note: Etidronate 200 mg and 400 mg tablets have been discontinued in the US for more than 1 year.

Heterotopic ossification, traumatic brain injury

Heterotopic ossification, traumatic brain injury: Limited data available: Children and Adolescents: Oral: Initial: 20 mg/kg/dose once daily for 2 to 4 weeks, then decrease to 10 mg/kg/dose once daily for 12 weeks to 1 year (Hurvitz 1992).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Manufacturer's labeling recommends decreasing the dose when GFR is reduced in adults; however, no specific dosage adjustments are provided. Use with caution and monitor closely; etidronate is eliminated intact via the kidneys.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Gastrointestinal: Diarrhea (≤30%; dose dependent), nausea (≤30%; dose dependent)

Neuromuscular & skeletal: Ostealgia (10% to 20%; dose dependent)

Postmarketing and/or case reports: Agranulocytosis, alopecia, amnesia, angioedema, arthralgia, arthritis, bone fracture, confusion, depression, erythema multiforme, esophagitis, exacerbation of asthma, exacerbation of peptic ulcer, folliculitis, gastritis, glossitis, glossopyrosis, hallucination, headache, hypersensitivity reaction, leg cramps, leukemia, leukopenia, maculopapular rash, osteomalacia, osteonecrosis of the jaw, pancytopenia, paresthesia, pruritus, skin rash (macular), Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria

Contraindications

Hypersensitivity to bisphosphonates or any component of the formulation; overt osteomalacia; patients with abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying

Warnings/Precautions

Concerns related to adverse effects:

• Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.

• Fracture risk: Do not exceed recommended dose or use continuously for >6 months in patients with Paget's disease; risk of osteomalacia or fractures may be increased. Long bones with predominantly lytic lesions may be prone to fracture, particularly in patients unresponsive to treatment.

• GI mucosa irritation: May cause irritation to upper GI mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.

• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates; this has been observed primarily following dental procedures such as tooth extractions and in cancer patients receiving IV bisphosphonates, but has also occurred in patients with postmenopausal osteoporosis and other diagnoses receiving oral bisphosphonates. Risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant chemotherapy, radiotherapy, or corticosteroids; anemia, coagulopathy, infection, ill-fitting dentures, or preexisting dental disease. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonate and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. The manufacturer’s labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for <4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for >4 years or in patients receiving oral bisphosphonates for <4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month drug free period prior to invasive dental procedures (recommendation based on a theoretical benefit). Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.

Disease-related concerns:

• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.

• Enterocolitis: Use with caution in patients with enterocolitis; diarrhea has been reported at high doses and therapy may need to be withheld.

• Renal impairment: Use with caution in patients with renal impairment.

Other warnings/precautions:

• Bone mineralization: May retard mineralization of bone; treatment may need delayed or interrupted until callus is present.

• Calcium/vitamin D intake: Ensure adequate calcium and vitamin D intake.

Warnings: Additional Pediatric Considerations

Prolonged therapy may lead to rachitic syndrome; doses of ≥10 mg/kg/day for ~1 year have been associated with rachitic syndrome when etidronate was used to prevent heterotopic ossifications or soft tissue calcifications; radiologic changes and symptoms have been reversed upon discontinuation.

Product Availability

Etidronate 200 mg and 400 mg tablets have been discontinued in the US for more than 1 year.

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Etidronate Disodium Oral)

200 mg (per each): $4.32

400 mg (per each): $8.64

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral, as disodium:

Generic: 200 mg [DSC], 400 mg [DSC]

Administration: Adult

Oral: Administer tablet on an empty stomach with a full glass of plain water (6 to 8 oz) 2 hours before food. Patients should be instructed to stay upright (not to lie down) after taking the medication. If gastrointestinal discomfort occurs, the dose may be divided.

Administration: Pediatric

Oral: Administer on an empty stomach with a full glass of plain water (6 to 8 oz), 2 hours before meals. Patients should be instructed to stay upright (not to lie down) after taking the medication. Dose should be taken once daily, however, if GI upset occurs, doses can be divided.

Use: Labeled Indications

Heterotopic ossification: Prevention and treatment of heterotopic ossification due to spinal cord injury or after total hip replacement

Paget disease: Symptomatic treatment of Paget disease of bone

Note: Not generally a recommended treatment option; guidelines recommend the use of more potent bisphosphonate therapy (eg, zoledronic acid) (Endocrine Society [Singer 2014]; Ralston 2019).

Medication Safety Issues
Sound-alike/look-alike issues:

Etidronate may be confused with etomidate

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives. Risk C: Monitor therapy

Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. Risk C: Monitor therapy

Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. Risk C: Monitor therapy

Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification

Technetium Tc 99m Medronate: Etidronate may diminish the diagnostic effect of Technetium Tc 99m Medronate. Management: Consider performing bone scintigraphy with technetium Tc 99m medronate before, or at least 2 to 4 weeks after, etidronate administration. Risk D: Consider therapy modification

Food Interactions

Food and/or supplements decrease the absorption and bioavailability of the drug. Management: Administer tablet on an empty stomach with a full glass of plain water or fruit juice (6 to 8 oz) 2 hours before food. Avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or other beverages.

Reproductive Considerations

Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011).

Pregnancy Considerations

It is not known if bisphosphonates cross the placenta, but based on their lower molecular weight, fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).

Information related to the use of etidronate in pregnancy is available from case reports and small retrospective studies (Agarwal 2020; Levy 2009; Sokal 2019; Vujasinovic-Stupar 2012).

Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).

Breastfeeding Considerations

It is not known if etidronate is present in breast milk.

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking considering the importance of treatment to the mother.

Dietary Considerations

Ensure adequate calcium and vitamin D intake; women and men >50 years of age should consume 1,200 to 1,500 mg/day of elemental calcium and 800 to 1,000 units/day of vitamin D. Tablet should be taken with water or fruit juice on an empty stomach; avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug. Do not take with mineral water or with other beverages.

Monitoring Parameters

Paget disease: Serum total alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~6- to 12-month intervals (Endocrine Society [Singer 2014]); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (Endocrine Society [Singer 2014]); pain (posttreatment pain may not strictly correlate with increased biochemical markers [Ralston 2019]); serum calcium and 25(OH)D.

Reference Range

Calcium (total): Adults: 9 to 11 mg/dL.

Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L).

Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:

Adults (IOM 2011): Sufficient levels in practically all persons: ≥20 ng/mL (50 nmol/L); concern for risk of toxicity: >50 ng/mL (125 nmol/L).

Mechanism of Action

Decreases bone resorption by inhibiting osteocytic osteolysis; decreases mineral release and matrix or collagen breakdown in bone

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: 1 to 3 months

Duration: Can persist for 12 months without continuous therapy

Absorption: ~3%

Metabolism: None

Half-life elimination: 1 to 6 hours

Excretion: Primarily urine (50% as unchanged drug); feces (as unabsorbed drug)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AR) Argentina: Difosfen;
  • (AT) Austria: Didronel;
  • (AU) Australia: Didronel;
  • (BE) Belgium: Didronel | Osteodidronel;
  • (CH) Switzerland: Didronel;
  • (CL) Chile: Osteotop;
  • (CN) China: Bang de lin | Etidronate disod. | Gen de | Yilin | Zhong bao bi xin;
  • (CO) Colombia: Difosfen;
  • (CZ) Czech Republic: Pleostat;
  • (DE) Germany: Didronate | Didronel | Diphos | Etidron hexal | Etidronat;
  • (DO) Dominican Republic: Difosfen | Osteol;
  • (EG) Egypt: Etidrone | Ossidron;
  • (ES) Spain: Difosfen | Osteum;
  • (FI) Finland: Didronate;
  • (FR) France: Didronel | Etidronate de Sodium G Gam | Etidronate de Sodium Merck;
  • (GB) United Kingdom: Didronel | Didronel brocades | Etidronate;
  • (GR) Greece: Osteoton;
  • (HK) Hong Kong: Didronel;
  • (IE) Ireland: Didronel;
  • (IL) Israel: Didronel;
  • (IN) India: Etifem;
  • (IT) Italy: Didronel;
  • (JP) Japan: Didronel;
  • (KR) Korea, Republic of: Adbon | Dinol | Osteum;
  • (LT) Lithuania: Pleostat;
  • (LU) Luxembourg: Didronel;
  • (MA) Morocco: Didronel;
  • (MY) Malaysia: Difosfen;
  • (NL) Netherlands: Didronel;
  • (NO) Norway: Didronate;
  • (NZ) New Zealand: Arrow-Etidronate | Didronel | Etidrate;
  • (PE) Peru: Osteotop;
  • (PK) Pakistan: Etinat;
  • (PL) Poland: Didronel | Difosfen | Ostedron;
  • (PR) Puerto Rico: Didronel;
  • (PT) Portugal: Didronel;
  • (SE) Sweden: Didronate | Etidrel;
  • (SG) Singapore: Difosfen;
  • (SI) Slovenia: Pleostat;
  • (SK) Slovakia: Pleostat;
  • (TH) Thailand: Difosfen;
  • (TN) Tunisia: Didronel;
  • (TR) Turkey: Didronat;
  • (TW) Taiwan: Etibon;
  • (UY) Uruguay: Difosfen;
  • (ZA) South Africa: Didronel
  1. Agarwal N, Agarwal U, Alfirevic Z, et al. Skeletal abnormalities secondary to antenatal etidronate treatment for suspected generalised arterial calcification of infancy. Bone Rep. 2020;12:100280. doi:10.1016/j.bonr.2020.100280 [PubMed 32490054]
  2. American Dental Association Council on Scientific Affairs. Dental Management of Patients Receiving Oral Bisphosphonate Therapy. JADA. 2006;137(8):1144-1150. http://jada.ada.org/article/S0002-8177(14)64960-6/pdf [PubMed 16873332]
  3. Author Unknown. Safety Update: Bone-Building Drugs: Risks Explained. Consum Rep Health. 2006;18(5):3.
  4. Bhalla AK. Management of Osteoporosis in a Pre-menopausal Woman. Best Pract Res Clin Rheumatol. 2010;24(3):313-327. [PubMed 20534366]
  5. Djokanovic N, Klieger-Grossmann C, and Koren G. Does Treatment With Bisphosphonates Endanger the Human Pregnancy? J Obstet Gynaecol Can. 2008;30(12):1146-1148. [PubMed 19175968]
  6. Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008;139(12):1674-1677. [PubMed 19047674]
  7. Etidronate disodium tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc; March 2017.
  8. Filleul O, Crompot E, and Saussez S. Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases. J Cancer Res Clin Oncol. 2010;136(8):1117-1124. [PubMed 20508948]
  9. French AE, Kaplan N, Lishner M, et al. Taking Bisphosphonates During Pregnancy. Can Fam Physician. 2003;49:1281-1282. [PubMed 14594094]
  10. Gray RE. Severe Reaction to Diphosphonate. BMJ. 1988;297(6655):1042.
  11. Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014;71(23):2029-2036. [PubMed 25404594]
  12. Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243-1251. [PubMed 22041409]
  13. Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs. 2011. http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.
  14. Hurvitz EA, Mandac BR, Davidoff G, Johnson JH, Nelson VS. Risk factors for heterotopic ossification in children and adolescents with severe traumatic brain injury. Arch Phys Med Rehabil. 1992;73(5):459-462. [PubMed 1580774]
  15. IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
  16. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. [PubMed 25414052]
  17. Levy S, Fayez I, Taguchi N, et al. Pregnancy Outcome Following in utero Exposure to Bisphosphonates. Bone. 2009;44(3):428-430. [PubMed 19059370]
  18. Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. J Oral Maxillofac Surg. 2010;68(2):243-253. [PubMed 19772941]
  19. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig. 2019;40(2). doi:10.1515/hmbci-2019-0021 [PubMed 31539355]
  20. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg. 2005;63(11):1567-1575. [PubMed 16243172]
  21. Mavrokokki T, Cheng A, Stein B, et al. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415-423. [PubMed 17307586]
  22. Mital MA, Garber JE, and Stinson JT. Ectopic Bone Formation in Children and Adolescents With Head Injuries: Its Management. J Pediatr Orthop. 1987;7(1):83-90. [PubMed 3098781]
  23. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Rev Bras Reumatol. 2012;52(4):580-593. [PubMed 22885424]
  24. Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579-604. doi: 10.1002/jbmr.3657. [PubMed 30803025]
  25. Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031. [PubMed 25234529]
  26. Ruggiero S, Gralow J, Marx RE, et al. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. J Clin Oncol. 2006;2(1):7-14.
  27. Silverman SL, Hurvitz EA, Nelson VS, et al. Rachitic Syndrome After Disodium Etidronate Therapy in an Adolescent. Arch Phys Med Rehabil. 1994;75(1):118-120. [PubMed 8291954]
  28. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-4422. [PubMed 25406796]
  29. Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019;30(1):221-229. [PubMed 30171300]
  30. Stathopoulos IP, Liakou CG, Katsalira A, et al. The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation. Hormones (Athens). 2011;10(4):280-291. [PubMed 22281884]
  31. Storm T, Thamsborg G, Steiniche T, et al. Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women With Postmenopausal Osteoporosis. N Engl J Med. 1990;322(18):1265-1271. [PubMed 2109197]
  32. Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int. 2012;32(3):819-823. [PubMed 21327429]
  33. Watts NB, Harris ST, Genant HK, et al. Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis. N Engl J Med. 1990;323(2):73-79. [PubMed 2113611]
  34. Whyte MP. Clinical Practice. Paget's Disease of Bone. N Engl J Med. 2006;355(6):593-600. [PubMed 16899779]
  35. Wysowski DK. Reports of Esophageal Cancer With Oral Bisphosphonate Use. N Engl J Med. 2009;360(1):89-90. [PubMed 19118315]
Topic 8426 Version 187.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟